Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

Daniel Helbling(University Hospital of Bern), Dieter Koeberle(Kantonsspital St. Gallen), Beat Gloor(University of Bern), G. Bodoky(Unified Szent István and Szent László Hospital), Daniela Baertschi(Swiss Group For Clinical Cancer Research), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Piercarlo Saletti(Institute of Oncology Research), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Lukas Werner Widmer(GastroZentrum Hirslanden Zürich), Fred T. Bosman(Leiden University Medical Center), Axel Madlung, Pu Yan(University Hospital Zurich), Ralph C. Winterhalder(Luzerner Kantonsspital), Daniel Rauch(Washington University in St. Louis), Markus Borner(University of Bern), Roger Burkhard(GastroZentrum Hirslanden Zürich)
Journal of Clinical Oncology
January 20, 2015
10.1200/jco.2015.33.3_suppl.762
Cited by 0

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835